Orion (ORNBV) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
26 Oct, 2026Opening remarks and agenda
AGM held on 20 March 2024 at Messukeskus Siipi conference centre in Helsinki; confirmed the parent and Group financial statements for FY2023.
Board and executive committee updates
Board set at eight members; Kari Jussi Aho, Maziar Mike Doustdar, Ari Lehtoranta, Veli-Matti Mattila, Hilpi Rautelin, Eija Ronkainen and Karen Lykke Sørensen re-elected; Henrik Stenqvist elected as a new member.
Veli-Matti Mattila elected Chairman; Board members and the President and CEO discharged from liability for FY2023.
Dividend announcements
Dividend of EUR 1.62 per share approved in two EUR 0.81 instalments: first payable 3 April 2024 (record date 22 March); second payable 23 October 2024 (record date 16 October).
Board authorised to set a new record date and payment date for the second instalment if required by changes to applicable rules or regulations.
Latest events from Orion
- Nubeqa-led growth lifted 9M sales 24.1% and operating profit 65.2%.ORNBV
Investor presentation - Nubeqa-led Q3 growth lifted operating profit 73.5% and drove higher FY26 guidance.ORNBV
Q3 2026 - Innovative Medicines and Nubeqa® fuel robust growth, with strong profits and global expansion.ORNBV
Investor presentation - Strong H1 2026 growth driven by Innovative Medicines and Nubeqa royalties; outlook raised.ORNBV
Q2 2026 - Net sales and profit surged in Q1, driven by NubeqaⓇ and Easyhaler®, with upgraded 2026 outlook.ORNBV
Q1 2026 - Q2 2025 net sales rose 27% and operating profit 59%, driven by NubeqaⓇ and innovative medicines.ORNBV
Q2 2025 - Net sales and profit surged on Nubeqa® milestones, prompting an upgraded 2024 outlook.ORNBV
Q3 2024 - Strong H1 growth and upgraded 2024 outlook driven by Nubeqa, Animal Health, and milestone deals.ORNBV
Q2 2024 - Growth driven by innovation, global expansion, and new biologics pipeline.ORNBV
CMD 2025